Journal Mobile Options
Table of Contents
Vol. 116, No. 1, 2010
Issue release date: June 2010
Cardiology 2010;116:37–41
(DOI:10.1159/000313465)

Preliminary Investigation of the Clinical Value of Vascular Endothelial Growth Factor and Hypoxia-Inducible Factor-1α in Pericardial Fluid in Diagnosing Malignant and Tuberculous Pericardial Effusion

Liu J. · Zeng Y. · Ma W. · Chen S. · Zheng Y. · Ye S. · Lan L. · Weig H.-J. · Liu Q.
aDepartment of Internal Cardiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, bCentral Hospital of Wuhan, Wuhan, China; cDepartment of Internal Cardiology, University Hospital of Tuebingen, University of Tuebingen, Tuebingen, Germany

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Objectives: To investigate the clinical value of vascular endothelial growth factor (VEGF) and hypoxia-inducible factor-1α (HIF-1α) in diagnosing malignant and tuberculous pericardial effusion. Methods: Eighty patients with exudative pericardial effusion undergoing pericardiocentesis and drainage were divided into 2 groups, namely those with malignancy and those with tuberculosis. The levels of HIF-1α, VEGF, lactate dehydrogenase (LDH) and adenosine deaminase (ADA) in pericardial fluid and serum were measured. Routine and cytological examination of pericardial fluid, clinical characteristics and some blood parameters were compared between the 2 groups. Results: There were 33 patients with tuberculous pericardial effusion and 47 with malignant pericardial effusion. The levels of VEGF and HIF-1α in pericardial fluid in the malignancy group were significantly higher than those in the tuberculosis group (p < 0.01), and there was a moderate positive correlation between the levels of VEGF and HIF-1α (r = 0.79, p < 0.01). The sensitivity and specificity of combining VEGF and HIF-1α were 90.8 and 88.3%, respectively. The 2 groups showed no differences with regard to gender distribution, occurrence of fever, erythrocyte sedimentation rate or the levels of hemoglobin, LDH, ADA, serum HIF-1α and VEGF. Conclusions: Both VEGF and HIF-1α in pericardial fluid have determinative value in the differential diagnosis of malignant and tuberculous pericardial effusion.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Xu CS, Wu YB, He T, Wang QX, Zhou QX, Zeng HS: Etiology of 384 cases with pericardial effusion (in Chinese). Lin Chuang Xin Xue Guan Bing Za Zhi 2008;24:794–795.
  2. Liu CJ, Tong BG, Xu LS, Cai NS, Ge JB: Clinical analysis of 206 cases with pericardial effusion (in Chinese).Yi Xue Wen Xuan 2006;25:217–218.
  3. Cornily JC, Pennec PY, Castellant P, Bezon E, Le Gal G, Gilard M, Jobic Y, Boschat J, Blanc JJ: Cardiac tamponade in medical patients: a 10-year follow-up survey. Cardiology 2008;111:197–201.
  4. Sugiura T, Kumon Y, Kataoka H, Matsumura Y, Takeuchi H, Doi Y: Asymptomatic pericardial effusion in patients with rheumatoid arthritis. Cardiology 2008;110:87–91.
  5. Rapose A, Sarvat B, Sarria JC: Immune reconstitution inflammatory syndrome presenting as pericarditis and pericardial effusion. Cardiology 2008;110:142–144.
  6. Mayosi BM, Burgess LJ, Doubell AF: Tuberculous pericarditis. Circulation 2005;112:3608–3616.
  7. Jiang BH, Liu LZ: PI3K/PTEN signaling in angiogenesis and tumorigenesis. Adv Cancer Res 2009;102:19–65.
  8. Grépin R, Pagès G: The vascular endothelial growth factor (VEGF): a model of gene regulation and a marker of tumour aggressiveness. An obvious therapeutic target? (in French). J Soc Biol 2009;203:181–192.
  9. Argyriou AA, Giannopoulou E, Kalofonos HP: Angiogenesis and anti-angiogenic molecularly targeted therapies in malignant gliomas. Oncology 2009;77:1–11.
  10. Fong GH: Regulation of angiogenesis by oxygen sensing mechanisms. J Mol Med 2009;87:549–560.
  11. Zhou WB, Bai M, Jin Y: Diagnostic value of vascular endothelial growth factor and endostatin in malignant pleural effusion. Int J Tuberc Lung Dis 2009;13:381–386.
  12. Hsu IL, Su WC, Yan JJ, Chang JM, Lai WW: Angiogenetic biomarkers in non-small cell lung cancer with malignant pleural effusion: correlations with patient survival and pleural effusion control. Lung Cancer 2009;65:371–376.
  13. Duysinx BC, Corhay JL, Hubin L, Nguyen D, Henket M, Louis R: Diagnostic value of interleukine-6, transforming growth factor-beta 1 and vascular endothelial growth factor in malignant pleural effusions. Respir Med 2008;102:1708–1714.
  14. Economidou F, Antoniou KM, Tzanakis N, Sfiridaki K, Siafakas NM, Schiza SE: Angiogenic molecule Tie-2 and VEGF in the pathogenesis of pleural effusions. Respir Med 2008;102:774–779.
  15. Shu J, Sun G, Liu H, Liu J: Clinical utility of vascular endothelial growth factor in diagnosing malignant pleural effusions. Acta Oncol 2007;46:1004–1011.
  16. Kaya A, Poyraz B, Celik G, Ciledag A, Gulbay BE, Savas H, Savas I: Vascular endothelial growth factor in benign and malignant pleural effusions (in Spanish). Arch Bronconeumol 2005;41:376–379.
  17. Sack U, Hoffmann M, Zhao XJ, Chan KS, Hui DS, Gosse H, Engelmann L, Schauer J, Emmrich F, Hoheisel G: Vascular endothelial growth factor in pleural effusions of different origin. Eur Respir J 2005;25:600–604.
  18. Hamed EA, El-Noweihi AM, Mohamed AZ, Mahmoud A: Vasoactive mediators (VEGF and TNF-alpha) in patients with malignant and tuberculous pleural effusions. Respirology 2004;9:81–86.
  19. Rafajlovski S, Tatić V, Ilić S, Kanjuh V: Frequency of metastatic tumors in the heart (in Serbian). Vojnosanit Pregl 2005;62:915–920.

    External Resources

  20. Koga S, Ikeda S, Urata J, Chijiwa R, Abe K, Hayashi T, Eishi K, Kohno S: Primary high-grade myofibroblastic sarcoma arising from the pericardium. Circ J 2008;72:337–339.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50